Tabula Rasa HealthCare Valuation
Is TRHC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Share Price vs Fair Value
What is the Fair Price of TRHC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate TRHC's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate TRHC's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for TRHC?
Other financial metrics that can be useful for relative valuation.
|What is TRHC's n/a Ratio?|
Price to Sales Ratio vs Peers
How does TRHC's PS Ratio compare to its peers?
|Company||PS||Estimated Growth||Market Cap|
AMWL American Well
SOPH SOPHiA GENETICS
HCAT Health Catalyst
TRHC Tabula Rasa HealthCare
Price-To-Sales vs Peers: TRHC is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (2x).
Price to Earnings Ratio vs Industry
How does TRHC's PE Ratio compare vs other companies in the US Healthcare Services Industry?
Price-To-Sales vs Industry: TRHC is good value based on its Price-To-Sales Ratio (0.8x) compared to the US Healthcare Services industry average (2.1x).
Price to Sales Ratio vs Fair Ratio
What is TRHC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||0.8x|
|Fair PS Ratio||0.6x|
Price-To-Sales vs Fair Ratio: TRHC is expensive based on its Price-To-Sales Ratio (0.8x) compared to the estimated Fair Price-To-Sales Ratio (0.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.